Summary: This ADC product is comprised of an anti-CD22 (clone hu10F4) monoclonal antibody conjugated via a MCC linker to DM1. The DM1 is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, DM1 binds to tubulins, interrupts microtubule dynamics, and subsequently, induces cell death. http://www.creative-biolabs.com/adc/target-cd22-10.htm